This article is based on the concluding remarks by the author at the Ninth Paavo Nurmi Symposium on 'Lipoproteins and the Pathobiology of the Arterial Intima'. . . . Circulating cholesterol is carried into the arterial intima, the site of atherogenesis, in low-density lipoprotein (LDL) particles, and from the intima back into the circulation in high-density lipoprotein (HDL) particles. At affected sites in the intima, cholesterol accumulates in deposits known as atheromas. These local accumulations are due to disturbances in the cholesterol flow through the intima, resulting in imbalance between inflow and outflow of cholesterol. The rate of cholesterol accumulation depends ultimately on the severity of the imbalance. The factor primarily responsible for this cholesterol imbalance appears to be local modification of LDL particles. Hence, to prevent accumulation of cholesterol in the intima, the production of modified LDL particles must be prevented. This can best be achieved by reducing the inflow of LDL particles into the intima. This, in turn, can be achieved by lowering the concentration of circulating LDL particles. In addition, increasing the concentration of circulating HDL particles should accelerate the rate of removal of cholesterol from the intima, so further improving the disturbed cholesterol balance at the atheromatous sites.

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/11.suppl_e.238DOI Listing

Publication Analysis

Top Keywords

ldl particles
20
cholesterol
10
particles intima
8
hdl particles
8
cholesterol intima
8
concentration circulating
8
intima
7
particles
7
ldl
5
atheroma formation
4

Similar Publications

Background: The atherogenic potential of remnant cholesterol, which refers to the cholesterol content of triglyceride-rich, non-low-density lipoprotein (LDL) particles in circulation, has gained increasing attention recently. Unfortunately, very limited information is available regarding remnant cholesterol levels in Indian subjects.

Methods: This was a retrospective study conducted at a premier, tertiary care center in North India.

View Article and Find Full Text PDF

The interplay of factors in metabolic syndrome: understanding its roots and complexity.

Mol Med

December 2024

Center for Cancer Immunology, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.

Metabolic syndrome (MetS) is an indicator and diverse endocrine syndrome that combines different metabolic defects with clinical, physiological, biochemical, and metabolic factors. Obesity, visceral adiposity and abdominal obesity, dyslipidemia, insulin resistance (IR), elevated blood pressure, endothelial dysfunction, and acute or chronic inflammation are the risk factors associated with MetS. Abdominal obesity, a hallmark of MetS, highlights dysfunctional fat tissue and increased risk for cardiovascular disease and diabetes.

View Article and Find Full Text PDF

Background: Low-Density Lipoprotein Cholesterol (LDL-C) is the primary lipid therapy target for coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI). However, progression of coronary atherosclerosis occurs even LDL-C controlled well, some potentially important factors have been overlooked.

Objective: This study aims to elucidate the relationship between remnant lipoprotein particle cholesterol (RLP-C) and the progression of non-target lesions (NTLs) in patients with well-controlled lipid levels after PCI.

View Article and Find Full Text PDF

Aim: In the PEMA-FL study in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), pemafibrate was shown to significantly decrease low-density lipoprotein cholesterol (LDL-C) levels. We aimed to investigate the mechanisms of pemafibrate-induced LDL-C reduction in patients with MASLD by conducting an additional sub-analysis of the PEMA-FL study.

Methods: The PEMA-FL study randomized 118 patients with MASLD to receive pemafibrate or placebo for 72 weeks.

View Article and Find Full Text PDF

Mass spectrometry lipidomics is becoming customary to analyse serum/plasma samples in epidemiology. The measurables are molecular constituents of lipoprotein particles, but very little is known on the consequences of adjusting lipidomics data with lipoprotein measures. We studied two population cohorts with 5,657 and 2,036 participants.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!